New hope for hemophilia a: Low-Dose emicizumab may protect joints better
NCT ID NCT07439055
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether switching to low-dose emicizumab can improve joint health and reduce bleeding in people with hemophilia A who still have joint problems despite standard factor VIII therapy. Eighteen patients aged 8-28 from Thailand were enrolled. Those with worse joint scores were switched to low-dose emicizumab, and their bleeding rates, joint health, and quality of life were tracked for 8 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- emicizumab
- What this could lead to
- If successful, low-dose emicizumab could offer better bleeding control and joint health for hemophilia A patients who don't respond well to standard factor VIII therapy.
- What could go wrong
- This is a small, early-phase study with only 18 participants, so results may not apply to everyone. The low dose may not work as well as higher doses, and long-term safety is unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A PATIENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chulalongkorn University
Bangkok, 10330, Thailand